Assessing diagnostic performance of plasma biomarkers in Alzheimer’s disease versus cognitively unimpaired individuals: P-tau217 emerges as the optimal marker in Chinese cohorts
P-tau217 stands out as a highly effective biomarker for distinguishing AD from CUC, exhibiting extensive clinical application potential in the Chinese population. It presents a promising array of clinical prospects for the Chinese population.
Authors
- Xiaodong Jia (ORCID: https://orcid.org/0000-0002-2145-6272)
- Haiyan Li (ORCID: https://orcid.org/0000-0002-1437-4383)
- Hailan Zhou
- Shinan Wang
- Na Zhan (ORCID: https://orcid.org/0000-0002-9043-2768)
- Wenying Yu (ORCID: https://orcid.org/0000-0003-1567-1723)
- Tong Li (ORCID: https://orcid.org/0000-0002-4283-0091)
- Keqiang Yan (ORCID: https://orcid.org/0000-0002-5124-9901)
- Liping Pan (ORCID: https://orcid.org/0000-0001-6172-3630)
- Dequan Liu (ORCID: https://orcid.org/0009-0003-1242-8792)
- Yujia Wang (ORCID: https://orcid.org/0000-0002-5264-521X)
- Yijun Song (ORCID: https://orcid.org/0000-0001-5215-6881)
- Baorong Chen
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Tianjin Medical University General Hospital (CN)
- Kingmed Diagnostics (CN)
- Hebei General Hospital (CN)
- Institute of Hematology & Blood Diseases Hospital (CN)
Publication Details
- Journal
- Frontiers in Aging Neuroscience
- Published
- 2025-03-26
- DOI
- https://doi.org/10.3389/fnagi.2025.1554805
- Citations
- 2
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 2.94